Search
VXA-CoV2-1
go.drugbank.com/drugs/DB16433InvestigationalVXA-CoV2-1 is a non-replicating adenoviral vector-based oral tableted vaccine candidate that expresses a SARS-CoV-2 antigen and dsRNA adjuvant[L30493]. … This oral vaccine aims to induce immunogenicity through induction of potent serum neutralizing antibodies to the SARS-CoV-2 spike protein, induction of mucosal immune responses, and induction of T-cell
IN01
go.drugbank.com/drugs/DB16434ExperimentalThese cultures contain EGF-4-EGF with the cholera toxin B-subunit domain G33D sequence[L30543]. … Of note, the IN01 vaccine is being tested in a Phase I clinical trial in patients with fibrosing interstitial lung disease resulting from SARS-CoV-2 infection (NCT04537130).
AdimrSC-2f
go.drugbank.com/drugs/DB16436InvestigationalA phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine[L30553, L30548]. … The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553].
Ganulameran
go.drugbank.com/drugs/DB16442InvestigationalAs such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). … Similar to [BNT162b2], BNT162b3 uses a nucleoside-modified RNA (modRNA) technology.
Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)
go.drugbank.com/drugs/DB16443InvestigationalThe Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853]. … These promising results have secured a Phase I trial (NCT04530656) to evaluate the safety, efficacy, and immunogenicity in healthy Chinese participants.
UB-612
go.drugbank.com/drugs/DB16444InvestigationalThe vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of a human IgG1, which facilitates cell attachment and acts as the principal neutralizing domain of the … This vaccine was designed to induce a broad immune response. It was able to reduce viral load and prevent COVID-19 infection in a mouse challenge model and in rhesus macaques[L30653, L30658].
Thymoquinone
go.drugbank.com/drugs/DB16447InvestigationalThymoquinone is a natural compound with widespread protective effects, including anti-oxidative, anti-inflammatory, immunomodulatory, anti-cancer, and anti-microbial.
Synonyms: 2-Isopropyl-5-methyl-p-benzoquinone, p-Cymene-2,5-dioneEfprezimod alfa
go.drugbank.com/drugs/DB16448InvestigationalCD24Fc is a biological immunomodulator originally developed to address graft-versus-host disease in stem cell transplantation in leukemia patients.
Rexin G
go.drugbank.com/drugs/DB16450InvestigationalRexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. … It is also being investigated for preventing SARSCOV-2 viral entry.
Synonyms: DeltaRex-G, Rexin GInternational brands: Rexin-GVeru-111
go.drugbank.com/drugs/DB16462InvestigationalThese trials aimed to evaluate its efficacy, safety, and tolerability in conditions such as SARS-CoV-2 infection, metastatic castration-resistant prostate cancer (mCRPC), respiratory distress syndrome
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingSynonyms: [2-(1H-indol-3-yl)-1H-imidazol-4-yl](3,4,5-trimethoxyphenyl)methanone, Methanone, [2-(1H-indol-3-yl)-1H-imidazol-5-yl](3,4,5-trimethoxyphenyl)-